BioPharma Resources

Drug Trial Radar · NCT03290248

Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

A Prospective, Controlled, Double Blind, Multi-Center, Randomized, 3 Arm, Phase 1b/2a Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 Delivered as an Intranasal Spray in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis

Last checked: Nov 19, 2026Latest source record: Nov 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

71

Actual

Start

Sep 19, 2017

Primary completion

Dec 21, 2018

Study completion Dec 21, 2018

Sponsor

Lead sponsor
AOBiome LLCIndustry
Sponsor type
Industry
Collaborators
Orange County Research Center; Integrium
First posted
Sep 21, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Prospective, Controlled, Double Blinded, Single Center, Randomized, 3 Arm, Parallel Assignment, Phase 1b/2a Study to assess the safety, tolerability, and preliminary efficacy of B244 delivered as an intranasal spray in healthy volunteers and subjects with seasonal allergic rhinitis.

Conditions

  • Allergic Rhinitis
  • Allergic Rhinitis Due to Grass Pollen
  • Healthy Volunteers

Interventions

  • B244 suspensionBiological

    B244 suspension in 30ml/bottle

  • VehicleBiological

    Vehicle, 30ml/bottle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0Time frame: Baseline to Day 28

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Orange County Research Center

    Tustin, California

  • Inflamax

    Mississauga, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.